Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
Oligodendrocyte death results in immune-mediated CNS demyelination.
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
Arzerra
Spin-offs: Meet the structure specialists
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
TGN1412: From Discovery to Disaster.
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Glatiramer acetate during early pregnancy: A prospective cohort study.
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.

Pages